Latest Neulasta news
FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections
posted June 5th
by modernClinician Editorial Team
by modernClinician Editorial Team
The first biosimilar drug to Neulasta has been approved by the U.S. Food and Drug Administration. Fulphila (pegfilgrastim) is approved for patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy and have symptoms of febrile neutropenia.
Most Speakers at FDA Advisory Committee Meetings Support Drug Approval 
Countries Involved in U.S. Clinical Trials Do Not Gain Timely Access to Approved Medicines 
FDA Suspends U.S. License of Chikungunya Vaccine Related Articles
Nearly 3 in 4 Older Adults Express Interest in Vaccine to Prevent Dementia 
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease 
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season 
Trends Reported in Vaccination Coverage for Adolescents for 2025 Monthly Specialist Briefings
Stay Connected
